Literature DB >> 16446403

Ubiquitination of p53 at multiple sites in the DNA-binding domain.

Wan Mui Chan1, Man Chi Mak, Tsz Kan Fung, Anita Lau, Wai Yi Siu, Randy Y C Poon.   

Abstract

The tumor suppressor p53 is negatively regulated by the ubiquitin ligase MDM2. The MDM2 recognition site is at the NH2-terminal region of p53, but the positions of the actual ubiquitination acceptor sites are less well defined. Lysine residues at the COOH-terminal region of p53 are implicated as sites for ubiquitination and other post-translational modifications. Unexpectedly, we found that substitution of the COOH-terminal lysine residues did not diminish MDM2-mediated ubiquitination. Ubiquitination was not abolished even after the entire COOH-terminal regulatory region was removed. Using a method involving in vitro proteolytic cleavage at specific sites after ubiquitination, we found that p53 was ubiquitinated at the NH2-terminal portion of the protein. The lysine residue within the transactivation domain is probably not essential for ubiquitination, as substitution with an arginine did not affect MDM2 binding or ubiquitination. In contrast, several conserved lysine residues in the DNA-binding domain are critical for p53 ubiquitination. Removal of the DNA-binding domain reduced ubiquitination and increased the stability of p53. These data provide evidence that in addition to the COOH-terminal residues, p53 may also be ubiquitinated at sites in the DNA-binding domain.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 16446403     DOI: 10.1158/1541-7786.MCR-05-0097

Source DB:  PubMed          Journal:  Mol Cancer Res        ISSN: 1541-7786            Impact factor:   5.852


  28 in total

Review 1.  Ubiquitin and ubiquitin-like modifications of the p53 family.

Authors:  Ian R Watson; Meredith S Irwin
Journal:  Neoplasia       Date:  2006-08       Impact factor: 5.715

2.  Extensive post-translational modification of active and inactivated forms of endogenous p53.

Authors:  Caroline J DeHart; Jasdave S Chahal; S J Flint; David H Perlman
Journal:  Mol Cell Proteomics       Date:  2013-09-20       Impact factor: 5.911

3.  Reciprocal negative regulation between the tumor suppressor protein p53 and B cell CLL/lymphoma 6 (BCL6) via control of caspase-1 expression.

Authors:  Min-Kyeong Kim; Ji-Yang Song; Dong-In Koh; Jin Young Kim; Masahiko Hatano; Bu-Nam Jeon; Min-Young Kim; Su-Yeon Cho; Kyung-Sup Kim; Man-Wook Hur
Journal:  J Biol Chem       Date:  2018-11-08       Impact factor: 5.157

4.  Cell fate decisions regulated by K63 ubiquitination of tumor necrosis factor receptor 1.

Authors:  Jürgen Fritsch; Mario Stephan; Vladimir Tchikov; Supandi Winoto-Morbach; Svetlana Gubkina; Dieter Kabelitz; Stefan Schütze
Journal:  Mol Cell Biol       Date:  2014-06-30       Impact factor: 4.272

5.  IRGM governs the core autophagy machinery to conduct antimicrobial defense.

Authors:  Santosh Chauhan; Michael A Mandell; Vojo Deretic
Journal:  Mol Cell       Date:  2015-04-16       Impact factor: 17.970

Review 6.  p53 N-terminal phosphorylation: a defining layer of complex regulation.

Authors:  Lisa M Miller Jenkins; Stewart R Durell; Sharlyn J Mazur; Ettore Appella
Journal:  Carcinogenesis       Date:  2012-04-12       Impact factor: 4.944

Review 7.  The Tail That Wags the Dog: How the Disordered C-Terminal Domain Controls the Transcriptional Activities of the p53 Tumor-Suppressor Protein.

Authors:  Oleg Laptenko; David R Tong; James Manfredi; Carol Prives
Journal:  Trends Biochem Sci       Date:  2016-09-23       Impact factor: 13.807

8.  Acetylation of the DNA binding domain regulates transcription-independent apoptosis by p53.

Authors:  Stephen M Sykes; Timothy J Stanek; Amanda Frank; Maureen E Murphy; Steven B McMahon
Journal:  J Biol Chem       Date:  2009-06-03       Impact factor: 5.157

Review 9.  Protein methylation: a new mechanism of p53 tumor suppressor regulation.

Authors:  A Scoumanne; X Chen
Journal:  Histol Histopathol       Date:  2008-09       Impact factor: 2.303

Review 10.  Modes of p53 regulation.

Authors:  Jan-Philipp Kruse; Wei Gu
Journal:  Cell       Date:  2009-05-15       Impact factor: 41.582

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.